Rituximab outperforms fingolimod after natalizumab switch

Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests.
Source: MedWire News - Category: Consumer Health News Tags: Multiple sclerosis Source Type: news